Thus, whether systemic therapies other than ET are needed to prevent distant metastasis and improve breast cancer mortality in HR‐positive patients and in HR‐negative or HER‐2‐positive patients with DCIS is unclear. Here, ERBB2 is linked to breast carcinoma.